バンコマイシン耐性腸球菌感染症 - 市場の洞察、疫学、市場予測：2034年

今後数年間で、バンコマイシン耐性腸球菌感染症市場は、この疾患に対する認識の高まりと、世界全体の医療支出の増加により変化するとみられます。

企業や研究機関は、バンコマイシン耐性腸球菌感染症の研究開発に影響を与えうる課題を評価し、その機会を探るべく取り組んでいます。開発中の治療法は、病態を治療/改善するための新規アプローチに焦点を当てています。主要企業はバンコマイシン耐性腸球菌感染症の治療法開発に関与しています。新たな治療法の登場は、バンコマイシン耐性腸球菌感染症市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるバンコマイシン耐性腸球菌感染症市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2034年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 バンコマイシン耐性腸球菌感染症のエグゼクティブサマリー

第3章 バンコマイシン耐性腸球菌感染症の競合情報分析

第4章 バンコマイシン耐性腸球菌感染症：市場概要

第5章 バンコマイシン耐性腸球菌感染症：疾患の背景と概要

• イントロダクション
• 兆候と症状
• 病態生理学
• 危険因子
• 診断

第6章 患者動向

第7章 バンコマイシン耐性腸球菌感染症の疫学と患者人口

• 疫学の主な調査結果
• 前提と根拠：主要7ヶ国
• 疫学シナリオ：主要7ヶ国
• 米国
• 欧州5ヶ国
• 日本疫学

第8章 治療アルゴリズム、現在の治療、医療行為

第9章 アンメットニーズ

第10章 バンコマイシン耐性腸球菌感染症治療の主要評価項目

第11章 上市済み製品

第12章 新たな治療法

第13章 バンコマイシン耐性腸球菌感染症：主要7ヶ国市場分析

第14章 属性分析

第15章 主要7ヶ国：市場見通し

• 米国：市場規模
• 欧州5ヶ国：市場規模と展望
• ドイツ市場規模
• フランス市場規模
• イタリア市場規模
• スペイン市場規模
• 英国市場規模
• 日本市場規模

第16章 バンコマイシン耐性腸球菌感染症のアクセスと償還の概要

第17章 KOLの見解

第18章 市場促進要因

第19章 市場の障壁

第20章 付録

第21章 DelveInsightのサービス内容

第22章 免責事項

第23章 DelveInsightについて

List of Tables

• Table 1: 7MM Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology (2020-2034)
• Table 2: 7MM Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases (2020-2034)
• Table 3: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in the United States (2020-2034)
• Table 4: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in the United States (2020-2034)
• Table 5: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Germany (2020-2034)
• Table 6: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Germany (2020-2034)
• Table 7: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in France (2020-2034)
• Table 8: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in France (2020-2034)
• Table 9: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Italy (2020-2034)
• Table 10: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Italy (2020-2034)
• Table 11: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Spain (2020-2034)
• Table 12: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Spain (2020-2034)
• Table 13: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in the UK (2020-2034)
• Table 14: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in the UK (2020-2034)
• Table 15: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Japan (2020-2034)
• Table 16: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Japan (2020-2034)
• Table 17: Drug Name, Clinical Trials by Recruitment status
• Table 18: Drug Name, Clinical Trials by Zone
• Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Table 20: Region-wise Market Size in USD, Million (2020-2034)
• Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Table 22: United States Market Size in USD, Million (2020-2034)
• Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Table 24: Germany Market Size in USD, Million (2020-2034)
• Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Table 26: France Market Size in USD, Million (2020-2034)
• Table 27: France Market Size by Therapy in USD, Million (2020-2034)
• Table 28: Italy Market Size in USD, Million (2020-2034)
• Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Table 30: Spain Market Size in USD, Million (2020-2034)
• Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Table 32: United Kingdom Market Size in USD, Million (2020-2034)
• Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Table 34: Japan Market Size in USD, Million (2020-2034)
• Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

• Figure 1: 7MM Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology (2020-2034)
• Figure 2: 7MM Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases (2020-2034)
• Figure 3: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in the United States (2020-2034)
• Figure 4: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in the United States (2020-2034)
• Figure 5: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Germany (2020-2034)
• Figure 6: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Germany (2020-2034)
• Figure 7: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in France (2020-2034)
• Figure 8: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in France (2020-2034)
• Figure 9: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Italy (2020-2034)
• Figure 10: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Italy (2020-2034)
• Figure 11: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Spain (2020-2034)
• Figure 12: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Spain (2020-2034)
• Figure 13: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in the UK (2020-2034)
• Figure 14: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in the UK (2020-2034)
• Figure 15: Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology in Japan (2020-2034)
• Figure 16: Vancomycin-Resistant Enterococcus Faecium Infections Diagnosed and Treatable Cases in Japan (2020-2034)
• Figure 17: Drug Name, Clinical Trials by Recruitment status
• Figure 18: Drug Name, Clinical Trials by Zone
• Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Figure 20: Region-wise Market Size in USD, Million (2020-2034)
• Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Figure 22: United States Market Size in USD, Million (2020-2034)
• Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Figure 24: Germany Market Size in USD, Million (2020-2034)
• Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Figure 26: France Market Size in USD, Million (2020-2034)
• Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
• Figure 28: Italy Market Size in USD, Million (2020-2034)
• Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Figure 30: Spain Market Size in USD, Million (2020-2034)
• Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
• Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Figure 34: Japan Market Size in USD, Million (2020-2034)
• Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of figures is not exhaustive; the final content may vary

DelveInsight's "Vancomycin-Resistant Enterococcus Faecium Infections - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Vancomycin-Resistant Enterococcus Faecium Infections, historical and forecasted epidemiology as well as the Vancomycin-Resistant Enterococcus Faecium Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Vancomycin-Resistant Enterococcus Faecium Infections market report provides current treatment practices, emerging drugs, Vancomycin-Resistant Enterococcus Faecium Infections market share of the individual therapies, current and forecasted Vancomycin-Resistant Enterococcus Faecium Infections market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Vancomycin-Resistant Enterococcus Faecium Infections treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Vancomycin-Resistant Enterococcus Faecium Infections Disease Understanding and Treatment Algorithm

The DelveInsight Vancomycin-Resistant Enterococcus Faecium Infections market report gives a thorough understanding of the Vancomycin-Resistant Enterococcus Faecium Infections by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Vancomycin-Resistant Enterococcus Faecium Infections.

Treatment

It covers the details of conventional and current medical therapies available in the Vancomycin-Resistant Enterococcus Faecium Infections market for the treatment of the condition. It also provides Vancomycin-Resistant Enterococcus Faecium Infections treatment algorithms and guidelines in the United States, Europe, and Japan.

Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology

The Vancomycin-Resistant Enterococcus Faecium Infections epidemiology division provide insights about historical and current Vancomycin-Resistant Enterococcus Faecium Infections patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Vancomycin-Resistant Enterococcus Faecium Infections epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology

The epidemiology segment also provides the Vancomycin-Resistant Enterococcus Faecium Infections epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Vancomycin-Resistant Enterococcus Faecium Infections Drug Chapters

Drug chapter segment of the Vancomycin-Resistant Enterococcus Faecium Infections report encloses the detailed analysis of Vancomycin-Resistant Enterococcus Faecium Infections marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Vancomycin-Resistant Enterococcus Faecium Infections clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Vancomycin-Resistant Enterococcus Faecium Infections treatment.

Vancomycin-Resistant Enterococcus Faecium Infections Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Vancomycin-Resistant Enterococcus Faecium Infections treatment.

Vancomycin-Resistant Enterococcus Faecium Infections Market Outlook

The Vancomycin-Resistant Enterococcus Faecium Infections market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Vancomycin-Resistant Enterococcus Faecium Infections market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Vancomycin-Resistant Enterococcus Faecium Infections market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Vancomycin-Resistant Enterococcus Faecium Infections market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Vancomycin-Resistant Enterococcus Faecium Infections market in 7MM.

The United States Market Outlook

This section provides the total Vancomycin-Resistant Enterococcus Faecium Infections market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Vancomycin-Resistant Enterococcus Faecium Infections market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Vancomycin-Resistant Enterococcus Faecium Infections market size and market size by therapies in Japan is also mentioned.

Vancomycin-Resistant Enterococcus Faecium Infections Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Vancomycin-Resistant Enterococcus Faecium Infections market or expected to get launched in the market during the study period 2020-2034. The analysis covers Vancomycin-Resistant Enterococcus Faecium Infections market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Vancomycin-Resistant Enterococcus Faecium Infections Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Vancomycin-Resistant Enterococcus Faecium Infections key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Vancomycin-Resistant Enterococcus Faecium Infections emerging therapies.

Reimbursement Scenario in Vancomycin-Resistant Enterococcus Faecium Infections

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Vancomycin-Resistant Enterococcus Faecium Infections domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Vancomycin-Resistant Enterococcus Faecium Infections market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Vancomycin-Resistant Enterococcus Faecium Infections Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Vancomycin-Resistant Enterococcus Faecium Infections, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Vancomycin-Resistant Enterococcus Faecium Infections epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Vancomycin-Resistant Enterococcus Faecium Infections are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Vancomycin-Resistant Enterococcus Faecium Infections market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Vancomycin-Resistant Enterococcus Faecium Infections market

Report Highlights:

• In the coming years, Vancomycin-Resistant Enterococcus Faecium Infections market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Vancomycin-Resistant Enterococcus Faecium Infections R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Vancomycin-Resistant Enterococcus Faecium Infections. Launch of emerging therapies will significantly impact the Vancomycin-Resistant Enterococcus Faecium Infections market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Vancomycin-Resistant Enterococcus Faecium Infections
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Vancomycin-Resistant Enterococcus Faecium Infections Report Insights

• Patient Population
• Therapeutic Approaches
• Vancomycin-Resistant Enterococcus Faecium Infections Pipeline Analysis
• Vancomycin-Resistant Enterococcus Faecium Infections Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Vancomycin-Resistant Enterococcus Faecium Infections Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Vancomycin-Resistant Enterococcus Faecium Infections Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Vancomycin-Resistant Enterococcus Faecium Infections market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Vancomycin-Resistant Enterococcus Faecium Infections total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Vancomycin-Resistant Enterococcus Faecium Infections market size during the forecast period (2024-2034)?
• At what CAGR, the Vancomycin-Resistant Enterococcus Faecium Infections market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Vancomycin-Resistant Enterococcus Faecium Infections market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Vancomycin-Resistant Enterococcus Faecium Infections market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Vancomycin-Resistant Enterococcus Faecium Infections?
• What is the historical Vancomycin-Resistant Enterococcus Faecium Infections patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Vancomycin-Resistant Enterococcus Faecium Infections in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Vancomycin-Resistant Enterococcus Faecium Infections?
• Out of all 7MM countries, which country would have the highest prevalent population of Vancomycin-Resistant Enterococcus Faecium Infections during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Vancomycin-Resistant Enterococcus Faecium Infections treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Vancomycin-Resistant Enterococcus Faecium Infections in the USA, Europe, and Japan?
• What are the Vancomycin-Resistant Enterococcus Faecium Infections marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Vancomycin-Resistant Enterococcus Faecium Infections?
• How many therapies are developed by each company for Vancomycin-Resistant Enterococcus Faecium Infections treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Vancomycin-Resistant Enterococcus Faecium Infections treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Vancomycin-Resistant Enterococcus Faecium Infections therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vancomycin-Resistant Enterococcus Faecium Infections and their status?
• What are the key designations that have been granted for the emerging therapies for Vancomycin-Resistant Enterococcus Faecium Infections?
• What are the global historical and forecasted market of Vancomycin-Resistant Enterococcus Faecium Infections?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Vancomycin-Resistant Enterococcus Faecium Infections market
• To understand the future market competition in the Vancomycin-Resistant Enterococcus Faecium Infections market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Vancomycin-Resistant Enterococcus Faecium Infections in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Vancomycin-Resistant Enterococcus Faecium Infections market
• To understand the future market competition in the Vancomycin-Resistant Enterococcus Faecium Infections market

Table of Contents

1. Key Insights

2. Executive Summary of Vancomycin-Resistant Enterococcus Faecium Infections

3. Competitive Intelligence Analysis for Vancomycin-Resistant Enterococcus Faecium Infections

4. Vancomycin-Resistant Enterococcus Faecium Infections: Market Overview at a Glance

• 4.1. Vancomycin-Resistant Enterococcus Faecium Infections Total Market Share (%) Distribution in 2020
• 4.2. Vancomycin-Resistant Enterococcus Faecium Infections Total Market Share (%) Distribution in 2034

5. Vancomycin-Resistant Enterococcus Faecium Infections: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Vancomycin-Resistant Enterococcus Faecium Infections Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Vancomycin-Resistant Enterococcus Faecium Infections Treatment and Management
• 8.2. Vancomycin-Resistant Enterococcus Faecium Infections Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Vancomycin-Resistant Enterococcus Faecium Infections Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Vancomycin-Resistant Enterococcus Faecium Infections: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Vancomycin-Resistant Enterococcus Faecium Infections Market Size in 7MM
• 13.3. Vancomycin-Resistant Enterococcus Faecium Infections Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Vancomycin-Resistant Enterococcus Faecium Infections Total Market Size in the United States
  • 15.1.2. Vancomycin-Resistant Enterococcus Faecium Infections Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Vancomycin-Resistant Enterococcus Faecium Infections Total Market Size in Germany
  • 15.3.2. Vancomycin-Resistant Enterococcus Faecium Infections Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Vancomycin-Resistant Enterococcus Faecium Infections Total Market Size in France
  • 15.4.2. Vancomycin-Resistant Enterococcus Faecium Infections Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Vancomycin-Resistant Enterococcus Faecium Infections Total Market Size in Italy
  • 15.5.2. Vancomycin-Resistant Enterococcus Faecium Infections Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Vancomycin-Resistant Enterococcus Faecium Infections Total Market Size in Spain
  • 15.6.2. Vancomycin-Resistant Enterococcus Faecium Infections Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Vancomycin-Resistant Enterococcus Faecium Infections Total Market Size in the United Kingdom
  • 15.7.2. Vancomycin-Resistant Enterococcus Faecium Infections Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Vancomycin-Resistant Enterococcus Faecium Infections Total Market Size in Japan
  • 15.8.3. Vancomycin-Resistant Enterococcus Faecium Infections Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Vancomycin-Resistant Enterococcus Faecium Infections

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.